Aduro Biotech, Inc. (ADRO) Rating Lowered to Sell at BidaskClub

BidaskClub lowered shares of Aduro Biotech, Inc. (NASDAQ:ADRO) from a hold rating to a sell rating in a report released on Tuesday, August 8th.

Several other analysts also recently commented on the stock. Canaccord Genuity set a $30.00 price target on shares of Aduro Biotech and gave the company a buy rating in a research report on Thursday, August 3rd. HC Wainwright set a $18.00 price target on shares of Aduro Biotech and gave the stock a buy rating in a research note on Thursday, August 3rd. Zacks Investment Research cut shares of Aduro Biotech from a buy rating to a hold rating in a research note on Wednesday, August 2nd. Cowen and Company initiated coverage on shares of Aduro Biotech in a research note on Tuesday, July 18th. They issued an outperform rating on the stock. Finally, Rodman & Renshaw initiated coverage on shares of Aduro Biotech in a research note on Monday, May 1st. They issued a buy rating and a $18.00 price objective on the stock. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the stock. The company has an average rating of Buy and a consensus price target of $19.00.

Aduro Biotech (ADRO) traded down 3.15% during midday trading on Tuesday, hitting $10.75. The company’s stock had a trading volume of 301,795 shares. Aduro Biotech has a 12 month low of $8.75 and a 12 month high of $15.83. The firm’s market cap is $802.08 million. The company’s 50 day moving average price is $12.44 and its 200 day moving average price is $10.98.

Aduro Biotech (NASDAQ:ADRO) last issued its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.25) by $0.02. The company had revenue of $5.90 million for the quarter, compared to analysts’ expectations of $3.98 million. Aduro Biotech had a negative return on equity of 43.92% and a negative net margin of 609.58%. The firm’s quarterly revenue was down 84.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.03 EPS. Analysts expect that Aduro Biotech will post ($1.37) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Aduro Biotech, Inc. (ADRO) Rating Lowered to Sell at BidaskClub” was first published by BNB Daily and is owned by of BNB Daily. If you are reading this news story on another domain, it was copied illegally and republished in violation of US and international copyright law. The legal version of this news story can be accessed at https://www.baseball-news-blog.com/2017/08/19/aduro-biotech-inc-adro-downgraded-to-sell-at-bidaskclub-updated.html.

In other news, insider Thomas W. Dubensky sold 144,301 shares of the firm’s stock in a transaction that occurred on Monday, June 5th. The shares were sold at an average price of $10.03, for a total transaction of $1,447,339.03. Following the completion of the sale, the insider now owns 117,871 shares of the company’s stock, valued at $1,182,246.13. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Jennifer Lew sold 6,600 shares of the firm’s stock in a transaction on Monday, August 7th. The stock was sold at an average price of $12.17, for a total value of $80,322.00. Following the transaction, the insider now owns 49,195 shares in the company, valued at $598,703.15. The disclosure for this sale can be found here. Insiders sold 561,624 shares of company stock valued at $6,232,065 in the last ninety days. 6.60% of the stock is owned by corporate insiders.

A number of large investors have recently bought and sold shares of the stock. The Manufacturers Life Insurance Company boosted its stake in Aduro Biotech by 12.5% in the second quarter. The Manufacturers Life Insurance Company now owns 33,964 shares of the biotechnology company’s stock worth $388,000 after buying an additional 3,769 shares during the last quarter. State Street Corp boosted its stake in Aduro Biotech by 8.3% in the second quarter. State Street Corp now owns 684,699 shares of the biotechnology company’s stock worth $7,808,000 after buying an additional 52,597 shares during the last quarter. Nexthera Capital LP bought a new stake in Aduro Biotech during the second quarter worth about $1,767,000. PDT Partners LLC bought a new stake in shares of Aduro Biotech during the second quarter worth $570,000. Finally, Voya Investment Management LLC boosted its stake in shares of Aduro Biotech by 15.3% in the second quarter. Voya Investment Management LLC now owns 18,935 shares of the biotechnology company’s stock worth $216,000 after buying an additional 2,515 shares in the last quarter. Institutional investors own 33.48% of the company’s stock.

About Aduro Biotech

Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.

Analyst Recommendations for Aduro Biotech (NASDAQ:ADRO)

Receive News & Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply